93 related articles for article (PubMed ID: 11050920)
1. [Paclitaxel versus doxorubicin in first-line therapy of metastatic breast carcinoma].
Tanner J; Kuhnt T
Strahlenther Onkol; 2000 Sep; 176(9):435-6. PubMed ID: 11050920
[No Abstract] [Full Text] [Related]
2. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
[TBL] [Abstract][Full Text] [Related]
3. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study.
Rigatos SK; Tsavdaridis D; Athanasiadis A; Stathopoulos JG; Stathopoulos GP
Oncol Rep; 2003; 10(6):1817-9. PubMed ID: 14534702
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomised phase II study.
Gebbia V; Blasi L; Borsellino N; Caruso M; Leonardi V; Agostara B; Valenza R
Anticancer Res; 2003; 23(1B):765-71. PubMed ID: 12680181
[TBL] [Abstract][Full Text] [Related]
6. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
Vorobiof DA; Rapoport BL; Chasen MR; Slabber C; McMichael G; Eek R; Mohammed C
Breast; 2004 Jun; 13(3):219-26. PubMed ID: 15177425
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
Biganzoli L; Cufer T; Bruning P; Coleman RE; Duchateau L; Rapoport B; Nooij M; Delhaye F; Miles D; Sulkes A; Hamilton A; Piccart M
Cancer; 2003 Jan; 97(1):40-5. PubMed ID: 12491503
[TBL] [Abstract][Full Text] [Related]
8. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P
J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
[TBL] [Abstract][Full Text] [Related]
10. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
Gennari A; Amadori D; De Lena M; Nanni O; Bruzzi P; Lorusso V; Manzione L; Conte PF
J Clin Oncol; 2006 Aug; 24(24):3912-8. PubMed ID: 16921042
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
Gianni L; Baselga J; Eiermann W; Guillem Porta V; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Llombart Cussac A; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez Lopez JJ; Mansutti M; Valagussa P; Bonadonna G;
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8715-21. PubMed ID: 16361558
[TBL] [Abstract][Full Text] [Related]
12. Use of dose-dense chemotherapy in the management of breast cancer.
Norton L
Clin Adv Hematol Oncol; 2006 Jan; 4(1):36-7. PubMed ID: 16562368
[No Abstract] [Full Text] [Related]
13. Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma.
Bower JH; Muenter MD
Mov Disord; 1995 Sep; 10(5):681-2. PubMed ID: 8552128
[No Abstract] [Full Text] [Related]
14. [Local radiotherapy and adriblastin chemotherapy in metastatic breast carcinoma].
Renner H; Zeinz M
Strahlentherapie Sonderb; 1978; 75():199-201. PubMed ID: 95495
[No Abstract] [Full Text] [Related]
15. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; McDermott D; Levine J; Warren D; McCauley M; Wheeler C; Frei E
Bone Marrow Transplant; 2001 Sep; 28(5):447-54. PubMed ID: 11593317
[TBL] [Abstract][Full Text] [Related]
16. [Doxorubicin and paclitaxel vs. 5-fluorouracyl, doxorubicin and cyclophosphamid in the first line treatment of metastatic breast cancer].
Nagykálnai T
Magy Onkol; 2002; 46(2):192-3. PubMed ID: 12202899
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
[TBL] [Abstract][Full Text] [Related]
18. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
19. [Cardiac tolerance of the combination paclitaxel-anthracyclines in the context of the management of cancer of the breast].
Ferrero JM; Magné N; Foa C; Largillier R; Namer M
Bull Cancer; 2003 Mar; 90(3):219-26. PubMed ID: 12801824
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
